[
    {
        "vaccineId": 31,
        "name": "IXCHIQ®",
        "pathogenId": 7
    },
    {
        "vaccineId": 32,
        "name": "Adenovirus Type 4",
        "pathogenId": 25
    },
    {
        "vaccineId": 33,
        "name": "Type 7 Vaccine, Live, Oral®",
        "pathogenId": 25
    },
    {
        "vaccineId": 34,
        "name": "BioThrax®",
        "pathogenId": 34
    },
    {
        "vaccineId": 35,
        "name": "CYFENDUS®",
        "pathogenId": 34
    },
    {
        "vaccineId": 36,
        "name": "Infanrix®",
        "pathogenId": 39
    },
    {
        "vaccineId": 37,
        "name": "Adacel®",
        "pathogenId": 39
    },
    {
        "vaccineId": 38,
        "name": "DAPTACEL®",
        "pathogenId": 39
    },
    {
        "vaccineId": 39,
        "name": "Boostrix®",
        "pathogenId": 39
    },
    {
        "vaccineId": 40,
        "name": "Diphtheria-Tetanus-Pertussis Vaccine Adsorbed®",
        "pathogenId": 39
    },
    {
        "vaccineId": 41,
        "name": "DTP Vaccine®",
        "pathogenId": 39
    },
    {
        "vaccineId": 42,
        "name": "TRIPVAC®",
        "pathogenId": 39
    },
    {
        "vaccineId": 43,
        "name": "DTwPHepatitisBHibadsorbed®",
        "pathogenId": 39
    },
    {
        "vaccineId": 44,
        "name": "DTwPHepatitisBHib®",
        "pathogenId": 39
    },
    {
        "vaccineId": 45,
        "name": "Easyfive TT®",
        "pathogenId": 39
    },
    {
        "vaccineId": 46,
        "name": "Eupenta®",
        "pathogenId": 39
    },
    {
        "vaccineId": 47,
        "name": "ComBE Five (Liquid)®",
        "pathogenId": 39
    },
    {
        "vaccineId": 48,
        "name": "ComBE Five (Reconstituted)®",
        "pathogenId": 39
    },
    {
        "vaccineId": 49,
        "name": "Pentabio®",
        "pathogenId": 39
    },
    {
        "vaccineId": 50,
        "name": "DTwPHib®",
        "pathogenId": 39
    },
    {
        "vaccineId": 51,
        "name": "KINRIX®",
        "pathogenId": 39
    },
    {
        "vaccineId": 52,
        "name": "Quadracel®",
        "pathogenId": 39
    },
    {
        "vaccineId": 53,
        "name": "PEDIARIX®",
        "pathogenId": 39
    },
    {
        "vaccineId": 54,
        "name": "Vaxelis®",
        "pathogenId": 39
    },
    {
        "vaccineId": 55,
        "name": "HEXASIIL®",
        "pathogenId": 39
    },
    {
        "vaccineId": 56,
        "name": "Infanrix Hexa®",
        "pathogenId": 39
    },
    {
        "vaccineId": 57,
        "name": "Pentacel®",
        "pathogenId": 39
    },
    {
        "vaccineId": 58,
        "name": "Hexacima; Hexaxim®",
        "pathogenId": 39
    },
    {
        "vaccineId": 59,
        "name": "Hexyon®",
        "pathogenId": 39
    },
    {
        "vaccineId": 62,
        "name": "BEtt®",
        "pathogenId": 41
    },
    {
        "vaccineId": 63,
        "name": "TETAVAX®",
        "pathogenId": 41
    },
    {
        "vaccineId": 64,
        "name": "TT vaccine®",
        "pathogenId": 41
    },
    {
        "vaccineId": 65,
        "name": "Tetanus Toxoid Vaccine Adsorbed®",
        "pathogenId": 41
    },
    {
        "vaccineId": 66,
        "name": "Tetatox®",
        "pathogenId": 41
    },
    {
        "vaccineId": 67,
        "name": "Tenivac®",
        "pathogenId": 41
    },
    {
        "vaccineId": 68,
        "name": "Adsorbed DT Vaccine®",
        "pathogenId": 41
    },
    {
        "vaccineId": 69,
        "name": "Diftet®",
        "pathogenId": 41
    },
    {
        "vaccineId": 70,
        "name": "ADSORBED Td VACCINE®",
        "pathogenId": 41
    },
    {
        "vaccineId": 71,
        "name": "BE Td®",
        "pathogenId": 41
    },
    {
        "vaccineId": 72,
        "name": "Diphtheria and Tetanus Vaccine Adsorbed (Paediatric)®",
        "pathogenId": 41
    },
    {
        "vaccineId": 73,
        "name": "Diphtheria and Tetanus Vaccine Adsorbed for Adults and Adolescents®",
        "pathogenId": 41
    },
    {
        "vaccineId": 74,
        "name": "IMOVAX dT adult®",
        "pathogenId": 41
    },
    {
        "vaccineId": 75,
        "name": "Infanrix®",
        "pathogenId": 41
    },
    {
        "vaccineId": 76,
        "name": "Tetadif®",
        "pathogenId": 41
    },
    {
        "vaccineId": 77,
        "name": "Adacel®",
        "pathogenId": 41
    },
    {
        "vaccineId": 78,
        "name": "DAPTACEL®",
        "pathogenId": 41
    },
    {
        "vaccineId": 79,
        "name": "Boostrix®",
        "pathogenId": 41
    },
    {
        "vaccineId": 80,
        "name": "Diphtheria-Tetanus-Pertussis Vaccine Adsorbed®",
        "pathogenId": 41
    },
    {
        "vaccineId": 81,
        "name": "DTP Vaccine®",
        "pathogenId": 41
    },
    {
        "vaccineId": 82,
        "name": "TRIPVAC®",
        "pathogenId": 41
    },
    {
        "vaccineId": 83,
        "name": "DTwPHepatitisBHibadsorbed®",
        "pathogenId": 41
    },
    {
        "vaccineId": 84,
        "name": "DTwPHepatitisBHib®",
        "pathogenId": 41
    },
    {
        "vaccineId": 85,
        "name": "Easyfive TT®",
        "pathogenId": 41
    },
    {
        "vaccineId": 86,
        "name": "Eupenta®",
        "pathogenId": 41
    },
    {
        "vaccineId": 87,
        "name": "ComBE Five (Liquid)®",
        "pathogenId": 41
    },
    {
        "vaccineId": 88,
        "name": "ComBE Five (Reconstituted)®",
        "pathogenId": 41
    },
    {
        "vaccineId": 89,
        "name": "Pentabio®",
        "pathogenId": 41
    },
    {
        "vaccineId": 90,
        "name": "DTwPHib®",
        "pathogenId": 41
    },
    {
        "vaccineId": 91,
        "name": "KINRIX®",
        "pathogenId": 41
    },
    {
        "vaccineId": 92,
        "name": "Quadracel®",
        "pathogenId": 41
    },
    {
        "vaccineId": 93,
        "name": "PEDIARIX®",
        "pathogenId": 41
    },
    {
        "vaccineId": 94,
        "name": "Vaxelis®",
        "pathogenId": 41
    },
    {
        "vaccineId": 95,
        "name": "HEXASIIL®",
        "pathogenId": 41
    },
    {
        "vaccineId": 96,
        "name": "Infanrix Hexa®",
        "pathogenId": 41
    },
    {
        "vaccineId": 97,
        "name": "Pentacel®",
        "pathogenId": 41
    },
    {
        "vaccineId": 98,
        "name": "Hexacima; Hexaxim®",
        "pathogenId": 41
    },
    {
        "vaccineId": 99,
        "name": "Hexyon®",
        "pathogenId": 41
    },
    {
        "vaccineId": 100,
        "name": "Hexyon®",
        "pathogenId": 41
    },
    {
        "vaccineId": 101,
        "name": "TDVAX®",
        "pathogenId": 35
    },
    {
        "vaccineId": 102,
        "name": "Tenivac®",
        "pathogenId": 35
    },
    {
        "vaccineId": 103,
        "name": "Adsorbed DT Vaccine®",
        "pathogenId": 35
    },
    {
        "vaccineId": 104,
        "name": "Diftet®",
        "pathogenId": 35
    },
    {
        "vaccineId": 105,
        "name": "ADSORBED Td VACCINE®",
        "pathogenId": 35
    },
    {
        "vaccineId": 106,
        "name": "BE Td®",
        "pathogenId": 35
    },
    {
        "vaccineId": 107,
        "name": "Diphtheria and Tetanus Vaccine Adsorbed (Paediatric)®",
        "pathogenId": 35
    },
    {
        "vaccineId": 108,
        "name": "Diphtheria and Tetanus Vaccine Adsorbed for Adults and Adolescents®",
        "pathogenId": 35
    },
    {
        "vaccineId": 109,
        "name": "IMOVAX dT adult®",
        "pathogenId": 35
    },
    {
        "vaccineId": 110,
        "name": "Tetadif®",
        "pathogenId": 35
    },
    {
        "vaccineId": 111,
        "name": "Adacel®",
        "pathogenId": 35
    },
    {
        "vaccineId": 112,
        "name": "DAPTACEL®",
        "pathogenId": 35
    },
    {
        "vaccineId": 113,
        "name": "Boostrix®",
        "pathogenId": 35
    },
    {
        "vaccineId": 114,
        "name": "Diphtheria-Tetanus-Pertussis Vaccine Adsorbed®",
        "pathogenId": 35
    },
    {
        "vaccineId": 115,
        "name": "Diphtheria-Tetanus-Pertussis Vaccine Adsorbed®",
        "pathogenId": 35
    },
    {
        "vaccineId": 116,
        "name": "DTP Vaccine®",
        "pathogenId": 35
    },
    {
        "vaccineId": 117,
        "name": "TRIPVAC®",
        "pathogenId": 35
    },
    {
        "vaccineId": 118,
        "name": "DTwPHepatitisBHibadsorbed®",
        "pathogenId": 35
    },
    {
        "vaccineId": 119,
        "name": "DTwPHepatitisBHib®",
        "pathogenId": 35
    },
    {
        "vaccineId": 120,
        "name": "Easyfive TT®",
        "pathogenId": 35
    },
    {
        "vaccineId": 121,
        "name": "Eupenta®",
        "pathogenId": 35
    },
    {
        "vaccineId": 122,
        "name": "ComBE Five (Reconstituted)®",
        "pathogenId": 35
    },
    {
        "vaccineId": 123,
        "name": "ComBE Five (Reconstituted)®",
        "pathogenId": 35
    },
    {
        "vaccineId": 124,
        "name": "Pentabio®",
        "pathogenId": 35
    },
    {
        "vaccineId": 125,
        "name": "DTwPHib®",
        "pathogenId": 35
    },
    {
        "vaccineId": 126,
        "name": "KINRIX®",
        "pathogenId": 35
    },
    {
        "vaccineId": 127,
        "name": "Quadracel®",
        "pathogenId": 35
    },
    {
        "vaccineId": 128,
        "name": "PEDIARIX®",
        "pathogenId": 35
    },
    {
        "vaccineId": 129,
        "name": "Vaxelis®",
        "pathogenId": 35
    },
    {
        "vaccineId": 130,
        "name": "HEXASIIL®",
        "pathogenId": 35
    },
    {
        "vaccineId": 131,
        "name": "Infanrix Hexa®",
        "pathogenId": 35
    },
    {
        "vaccineId": 132,
        "name": "Pentacel®",
        "pathogenId": 35
    },
    {
        "vaccineId": 133,
        "name": "Hexacima; Hexaxim®",
        "pathogenId": 35
    },
    {
        "vaccineId": 134,
        "name": "Hexyon®",
        "pathogenId": 35
    },
    {
        "vaccineId": 134,
        "name": "Hexyon®",
        "pathogenId": 35
    },
    {
        "vaccineId": 135,
        "name": "Dengvaxia®",
        "pathogenId": 30,
        "licensingDates": [
            {
                "name": "EMA",
                "type": "Approval",
                "date": "18/12/2018",
                "source": "https://docs.google.com/presentation/d/1wVeDY40TY1c2HTit7KpCc8yFCA4MGSe9/edit#slide=id.p1"
            },
            {
                "name": "FDA",
                "type": "Approval",
                "date": "01/05/2019",
                "source": "https://docs.google.com/presentation/d/1wVeDY40TY1c2HTit7KpCc8yFCA4MGSe9/edit#slide=id.p2"
            },
            {
                "name": "WHO",
                "type": "Approval",
                "date": "25/03/2020",
                "source": "https://docs.google.com/presentation/d/1wVeDY40TY1c2HTit7KpCc8yFCA4MGSe9/edit#slide=id.p3"
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Dengvaxia® (MAH: Sanofi)",
                "composition": "Chimeric Yellow Fever Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 3 years",
                "strainCoverage": "Dengue virus, all 4 virus serotypes.",
                "indication": "Dengue prevention against all 4 serotypes in individuals 6-45 years of age with test-confirmed previous dengue infection. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity; immunocompromised patients*; pregnancy; breastfeeding ",
                "dosing": "3 S.C. (e.g. in the deltoid region) doses (0.5 mL each); 6-month intervals.",
                "immunogenicity": "Higher antibody responses in adults versus children after 3 doses.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "Pooled VEy vs. symptomatic VCD, children 6-16 years: 62-64% x 25 mo f/u; seropositives: 79.7 – 79.9%VEy-bridging to adults: Immunogenicity after 3 doses is higher in adults than in children, no VEy data.",
                "durationOfProtection": "VEy in year 5 and 6: 14% in subjects 6-16 years with previous DV-infection.",
                "coAdministration": "Before the use of IgG: 6 wk.- 3 mo. waiting period; TdaP with Dengvaxia first dose: equal responses vs. sequential dosing; only descriptive data with bivalent HPV (similar GMTs co-ad vs sequential) and quadrivalent HPV (ratios in GMT from 0.8 to 1 for co-ad vs sequential) vaccines.",
                "reactogenicity": "Headache (51%), pain (49%), malaise (41%), myalgia (41%), asthenia (32%), fever (14%) – independent of serostatus prior to vaccination.",
                "safety": "Increased risk of severe Dengue in not-previously DV-infected subjects, mainly 3 years after 1st dose.",
                "vaccinationGoal": "Individual protection",
                "others": "No notes."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Dengvaxia® (MAH: Sanofi)",
                "composition": "Chimeric Yellow Fever Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 3 years",
                "strainCoverage": "Dengue virus, all 4 virus serotypes.",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals 6 to 16 years of age with test-confirmed previous dengue infection and living in endemic areas. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity, immunocompromised patients*.",
                "dosing": "3 S.C. (e.g. in the deltoid region) doses (0.5 mL each); 6-month intervals.",
                "immunogenicity": "No data are available.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy against VCD (dengue with acute febrile illness (temperature ≥38°C on at least 2 consecutive days) confirmed by dengue RT-PCR (any serotype) and/or dengue non-structural protein 1 (NS1) ELISA Antigen Test) after 3 doses x 12 mo. f/u, 9-16 years: 80.6 % (CI 95% = 50.7, 93.2); 6-14 years: 79.5 % (CI 95% = 44.2, 93.5)",
                "durationOfProtection": "No data are available.",
                "coAdministration": "tuberculin PPD testing: before vaccination or at least 1 month following vaccination.",
                "reactogenicity": "9-16 years: headache (40%), injection site pain (32%), malaise (25%), weakness (25%), myalgia (29%); 6-8 years: headache (27%), injection site pain (28%), malaise (19%), weakness (13%), and myalgia (15%).",
                "safety": "Increased risk of severe Dengue in not-previously DV-infected subjects.",
                "vaccinationGoal": "Individual protection",
                "others": "Safety and effectiveness in the geriatric population (65 years of age and older), pregnant women, and breastfeeding have not been established."
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Dengvaxia® (MAH: Sanofi)",
                "composition": "Chimeric Yellow Fever Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 3 years",
                "strainCoverage": "Dengue virus, all 4 virus serotypes.",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals 6 to 45 years of age with test-confirmed previous dengue infection. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity, immunocompromised patients; pregnancy; breastfeeding.",
                "dosing": "3 S.C. (e.g. in the deltoid region) doses (0.5 mL each); 6-month intervals.",
                "immunogenicity": "Higher antibody responses in adults versus children.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "Pooled VEy vs. symptomatic VCD, children 6-16 years: 62-64% x 25 mo f/u; seropositives: 79.7 – 79.9% VEy-bridging to adults: Immunogenicity after 3 doses is higher in adults than in children, no VEy data.",
                "durationOfProtection": "VEy in year 5 and 6: 14% in subjects 6-16 years with previous DV-infection.",
                "coAdministration": "Before the use of IgG: 6 wk- 3 mo waiting period; can be co-administer with Tdap and HPV vaccines.",
                "reactogenicity": "Very common (1 in 10 people): Headache, myalgia, malaise, myalgia, weakness, fever, erythema.",
                "safety": "Increased risk of severe Dengue in not-previously DV-infected subjects, mainly 3 years after 1st dose.",
                "vaccinationGoal": "Individual protection",
                "others": "Vaccination is not recommended for travelers who have never lived in an endemic area."
            }
        ]
    },
    {
        "vaccineId": 136,
        "name": "Qdenga®",
        "pathogenId": 30,
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Qdenga® (MAH: Takeda)",
                "composition": "Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 18 months",
                "strainCoverage": "Dengue tetravalent (all 4 virus serotypes) vaccine",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals > 4 years of age. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity; acute febrile illness; immunosuppressed individuals*; pregnancy; breastfeeding.",
                "dosing": "Two S.C. doses (0.5 mL each) e.g. in the deltoid region; 3-month intervals.",
                "immunogenicity": "In the absence of correlates of protection for dengue, the clinical relevance of immunogenicity data remains to be fully understood.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy in preventing VCD fever in children 4-16 years: 80.2% (CI 95% = 73.3, 85.3); VEy in preventing hospitalizations due to VCD fever: 90.4 (CI 95% =  82.6, 94.7.",
                "durationOfProtection": "VEy in preventing VCD fever and hospitalizations in children 4-16 years 4.5 years after vaccination: 84.1% (CI 95% = 77.8, 88.6).",
                "coAdministration": "Before use of IgG: 6 wk. - 3 mo. waiting period; can be administered with HepA vaccine (adults) or yellow fever vaccine.",
                "reactogenicity": "Injection site pain (50%), headache (35%), myalgia (31%), injection site erythema (27%), malaise (24%), weakness (20%) and fever (11%).",
                "safety": "Transient vaccine viremia was observed after 1st dose in 49% of study participants never infected and in 16% of study participants who had been previously infected. Vaccine viraemia was rarely detected after the second dose. ",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "Safety and efficacy of Qdenga in <4 years not yet established; no data on the use >60 years; limited data in patients with chronic medical conditions; no clinical efficacy study available in subjects >17 years of age, clinical efficacy for >17 years has been inferred from the clinical efficacy in 4-16 years."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Qdenga® (MAH:Takeda)",
                "composition": "-",
                "strainCoverage": "-",
                "indication": "-",
                "contraindication": "-",
                "dosing": "-",
                "immunogenicity": "-",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "-",
                "durationOfProtection": "-",
                "coAdministration": "-",
                "reactogenicity": "-",
                "safety": "-",
                "vaccinationGoal": "-",
                "others": "-"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Qdenga® (MAH:Takeda)",
                "composition": "Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 18 months",
                "strainCoverage": "Dengue tetravalent (all 4 virus serotypes) vaccine",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals > 6 years of age. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity; acute febrile illness; immunosuppressed individuals*; pregnancy; breastfeeding.",
                "dosing": "Two S.C. doses (0.5 mL each) e.g. in the deltoid region; 3-month intervals.",
                "immunogenicity": "In the absence of correlates of protection for dengue, the clinical relevance of immunogenicity data remains to be fully understood.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy in preventing VCD fever in children 4-16 years: 80.2% (CI 95% = 73.3, 85.3); VEy in preventing hospitalizations due to VCD fever: 90.4 (CI 95% =  82.6, 94.7)",
                "durationOfProtection": "VEy in preventing VCD fever and hospitalizations in children 4-16 years 4.5 years after vaccination: 84.1% (CI 95% = 77.8, 88.6).",
                "coAdministration": "Before use of IgG: 6 wk. - 3 mo. waiting period; can be administered with HepA vaccine (adults) or yellow fever vaccine.",
                "reactogenicity": "Very common (>10%): injection site pain or redness, headache, muscle pain, generally feeling unwell, weakness, infections of the nose or throat, fever.",
                "safety": "Transient vaccine viremia was observed after 1st dose in 49% of study participants never infected and in 16% of study participants who had been previously infected. Vaccine viraemia was rarely detected after the second dose. ",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "No data in adults above 60 years of age."
            }
        ]
    },
    {
        "vaccineId": 137,
        "name": "Ervebo®",
        "pathogenId": 29
    },
    {
        "vaccineId": 138,
        "name": "Zabdeno+Mvabea®",
        "pathogenId": 29
    },
    {
        "vaccineId": 139,
        "name": "ActHIB; Act-HIB®",
        "pathogenId": 40
    },
    {
        "vaccineId": 140,
        "name": "Haemophilus influenzae type b Conjugate Vaccine®",
        "pathogenId": 40
    },
    {
        "vaccineId": 141,
        "name": "HIBERIX®",
        "pathogenId": 40
    },
    {
        "vaccineId": 142,
        "name": "HIBERIX®",
        "pathogenId": 40
    },
    {
        "vaccineId": 143,
        "name": "Liquid PedvaxHIB®",
        "pathogenId": 40
    },
    {
        "vaccineId": 144,
        "name": "Quimi Hib®",
        "pathogenId": 40
    },
    {
        "vaccineId": 145,
        "name": "DTwPHepatitisBHibadsorbed®",
        "pathogenId": 40
    },
    {
        "vaccineId": 146,
        "name": "DTwPHepatitisBHib®",
        "pathogenId": 40
    },
    {
        "vaccineId": 147,
        "name": "Easyfive TT®",
        "pathogenId": 40
    },
    {
        "vaccineId": 148,
        "name": "Eupenta®",
        "pathogenId": 40
    },
    {
        "vaccineId": 149,
        "name": "ComBE Five (Liquid)®",
        "pathogenId": 40
    },
    {
        "vaccineId": 150,
        "name": "ComBE Five (Reconstituted)®",
        "pathogenId": 40
    },
    {
        "vaccineId": 151,
        "name": "Pentabio®",
        "pathogenId": 40
    },
    {
        "vaccineId": 152,
        "name": "DTwPHib®",
        "pathogenId": 40
    },
    {
        "vaccineId": 153,
        "name": "Vaxelis®",
        "pathogenId": 40
    },
    {
        "vaccineId": 154,
        "name": "HEXASIIL®",
        "pathogenId": 40
    },
    {
        "vaccineId": 154,
        "name": "Infanrix Hexa®",
        "pathogenId": 40
    },
    {
        "vaccineId": 155,
        "name": "Pentacel®",
        "pathogenId": 40
    },
    {
        "vaccineId": 156,
        "name": "Pentacel®",
        "pathogenId": 40
    },
    {
        "vaccineId": 157,
        "name": "Hexacima; Hexaxim®",
        "pathogenId": 40
    },
    {
        "vaccineId": 158,
        "name": "Hexyon®",
        "pathogenId": 40
    },
    {
        "vaccineId": 159,
        "name": "Gardasil 9®",
        "pathogenId": 6
    },
    {
        "vaccineId": 160,
        "name": "Cecolin®",
        "pathogenId": 6
    },
    {
        "vaccineId": 161,
        "name": "Cervarix®",
        "pathogenId": 6
    },
    {
        "vaccineId": 162,
        "name": "Walrinvax®",
        "pathogenId": 6
    },
    {
        "name": "Abrysvo®",
        "vaccineId": 1,
        "pathogenId": 1,
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ],
        "licensers": [
            {
                "licenserId": 1,
                "link": "https://www.fda.gov/media/168889/download?attachment"
            },
            {
                "licenserId": 2,
                "link": "https://www.ema.europa.eu/en/documents/product-information/abrysvo-epar-product-information_en.pdf"
            }
        ],
        "licensingDates": [
            {
                "name": "EMA",
                "type": "Approval",
                "date": "15/09/2023",
                "source": "https://docs.google.com/presentation/d/12YarRyDG37tD5lL1nYr3MgtyXg3LPqUp/edit#slide=id.p1"
            },
            {
                "name": "FDA",
                "type": "Approval",
                "date": "31/05/2023",
                "source": "https://docs.google.com/presentation/d/12YarRyDG37tD5lL1nYr3MgtyXg3LPqUp/edit#slide=id.p3"
            }
        ],
        "approvalDate": "2023",
        "description": "Abrysvo™ is a vaccine developed by Pfizer to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in certain populations.",
        "introduction": {
            "General Information": {
                "Map Vaccine Preventable Diseases": "Map by disease",
                "Vaccine SmPCs (FDA, EMA, WHO, others)": "Search by disease, include combos",
                "Product profiles": "Pfizer's Abrysvo is approved for two key populations: pregnant individuals (for protecting infants) and older adults.",
                "Pipeline products - summary table": "Phase 3 studies ongoing, showing strong safety and immunogenicity data.",
                "Failed products": "None known."
            },
            "Company products, pipeline": {
                "VPD-BoD, Product presentations, Monograph": "Available as injection.",
                "Pivotal publications / data vaccines": "Published Phase 3 trials showing positive safety and efficacy results.",
                "Interviews": "Interviews with leading researchers discussing vaccine progress and approvals.",
                "Relevant literature": "Scientific articles on RSV vaccines and Abrysvo’s maternal immunization strategy.",
                "Pipeline products - detailed information (TPP)": "Phase 3 trials for additional age groups."
            }
        },
        "productProfiles": [
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Abrysvo™ (Pfizer)<br/>Respiratory Syncytial Virus (RSV) vaccine",
                "composition": "Abrysvo contains RSVPreF, a protein-based vaccine designed to prevent RSV infections in targeted populations.",
                "strainCoverage": "RSV strains A and B.",
                "indication": "Protects infants from birth to 6 months from RSV-related lower respiratory tract disease (LRTD) when administered between 32 to 36 weeks of pregnancy. Prevents LRTD caused by RSV in older adults.",
                "dosing": "Single-dose intramuscular injection.",
                "immunogenicity": "Demonstrated strong immune response in pregnant women and older adults, with high neutralizing antibody levels against RSV.",
                "efficacyEndpointsPhase3": "Reduction in RSV-related lower respiratory tract disease in infants and older adults.",
                "efficacyData": "Results show a significant decrease in severe RSV cases.",
                "durationOfProtection": "Several months, with research ongoing on long-term immunity.",
                "coAdministration": "Tested with flu vaccines; data supports co-administration in older adults.",
                "reactogenicity": "Common side effects include pain at the injection site, fatigue, headache, and muscle pain.",
                "safety": "Safe for both pregnant individuals and older adults, with no significant adverse events reported.",
                "vaccinationGoal": "Prevent severe RSV infections, particularly in vulnerable groups like newborns and the elderly.",
                "others": "FDA-approved for older adults and pregnant women. Phase 3 trials underway for expanded age groups."
            },
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Abrysvo™",
                "composition": "-",
                "strainCoverage": "-",
                "indication": "-",
                "contraindication": "-",
                "dosing": "-",
                "immunogenicity": "-",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "-",
                "durationOfProtection": "-",
                "coAdministration": "-",
                "reactogenicity": "-",
                "safety": "-",
                "vaccinationGoal": "-",
                "others": "-"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Abrysvo™ ",
                "composition": "-",
                "strainCoverage": "-",
                "indication": "-",
                "contraindication": "-",
                "dosing": "-",
                "immunogenicity": "-",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "-",
                "durationOfProtection": "-",
                "coAdministration": "-",
                "reactogenicity": "-",
                "safety": "-",
                "vaccinationGoal": "-",
                "others": "-"
            }
        ],
        "link": "https://www.pfizer.com/products/product-detail/abrysvotm",
        "lastUpdated": "2024-AUG"
    }
]